Psoriasis is associated with kidney disease, heart problems, diabetes, etc

Created November 2015

Kidney disease and psoriasis: novel evidences beyond old concepts

Clinical Rheumatology, First online: 28 November 2015

Luca Visconti , Giuseppe Leonardi, Michele Buemi, Domenico Santoro, Valeria Cernaro, Carlo Alberto Ricciardi, Antonio Lacquaniti, Giuseppe Coppolino

* Diseases that may be related via low vitamin D {include}

Psoriasis is an immune-mediated inflammatory disease for a long time considered as a type of pathology characterized by an exclusive skin involvement. Recently it has been shown that patients affected by this disease have a higher risk of developing comorbidities such as

cardiovascular diseases,
arterial hypertension,
diabetes mellitus, and
metabolic syndrome.

Even the kidneys can be affected by psoriasis through three different mechanisms: immune-mediated renal damage, drug-related renal damage and chronic renal damage. Renal function should be monitored periodically to minimize the risk of renal adverse events.

Publisher wants $40 for the PDF

References

Svedbom A, Dalén J, Mamolo C et al (2015) Increased cause-specific mortality in patients with mild and severe psoriasis: a population-based Swedish register study. Acta Derm Venereol 95:809–815PubMed

Menter A, Griffiths CE, Tebbey PW, Horn EJ, Sterry W (2010) International Psoriasis Council. Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community. J Eur Acad Dermatol Venereol 24:1371–1377CrossRefPubMed

Henseler T, Christophers E (1985) Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13:450–456CrossRefPubMed

Nestle FO, Kaplan DH, Barker J (2009) Psoriasis. N Engl J Med 361:496–509CrossRefPubMed

Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263–271CrossRefPubMed

Paneni F, Osto E, Costantino S et al (2013) Deletion of the activated protein-1 transcription factor JunD induces oxidative stress and accelerates age-related endothelial dysfunction. Circulation 127:1229–1240CrossRefPubMed

Green MS, Prystowsky JH, Cohen SR, Cohen JI, Lebwohl MG (1996) Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 34:911–914CrossRefPubMed

Menter A, Griffiths CE (2007) Current and future management of psoriasis. Lancet 370:272–284CrossRefPubMed

Cassano N, Vestita M, Panaro M, Carbonara M, Vena GA (2011) Renal function in psoriasis patients. Eur J Dermatol 21:264–265PubMed

10.

Chiu HY, Huang HL, Li CH et al (2015) Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. Br J Dermatol 173:146–154CrossRefPubMed

11.

Singh NP, Prakash A, Kubba S et al (2005) Psoriatic nephropathy does an entity exist? Ren Fail 27:123–127PubMed

12.

Zadrazil J, Tichý T, Horák P et al (2006) IgA nephropathy associated with psoriasis vulgaris: a contribution to the entity of “psoriatic nephropathy”. J Nephrol 19:382–386PubMed

13.

Sakemi T, Hayashida R, Ikeda Y, Baba N, Nishihara G, Kohda H (1996) Membranous glomerulonephropathy associated with psoriasis vulgaris. Nephron 72:351–352CrossRefPubMed

14.

Guilhou JJ, Clot J, Meynadier J, Lapinski H (1976) Immunological aspects of psoriasis. I. Immunoglobulins and anti-IgG factors. Br J Dermatol 94:501–507CrossRefPubMed

15.

Hall RP, Peck GL, Lawley TJ (1983) Circulating IgA immune complexes in patients with psoriasis. J Investig Dermatol 80:465–468CrossRefPubMed

16.

Lindqvist U, Rudsander A, Boström A, Nilsson B, Michaëlsson G (2002) IgA antibodies to gliadin and coeliac disease in psoriatic arthritis. Rheumatology 41:31–37CrossRefPubMed

17.

Damasiewicz-Bodzek A, Wielkoszyński T (2012) Advanced protein glycation in psoriasis. J Eur Acad Dermatol Venereol 26:172–179CrossRefPubMed

18.

Coppolino G, Bolignano D, Campo S, Loddo S, Teti D, Buemi M (2008) Circulating progenitor cells after cold pressor test in hypertensive and uremic patients. Hypertens Res 31:717–724CrossRefPubMed

19.

Wittenberg GP, Oursler JR, Peters MS (1995) Secondary amyloidosis complicating psoriasis. J Am Acad Dermatol 32:465–468CrossRefPubMed

20.

Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA (1983) The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094–1104CrossRefPubMed

21.

Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694–703CrossRefPubMed

22.

Buemi M, Floccari F, Costa C et al (2006) Dialysis-related genotoxicity: sister chromatid exchanges and DNA lesions in T and B lymphocytes of uremic patients. Genomic damage in patients on hemodiafiltration. Blood Purif 24:569–574CrossRefPubMed

23.

Furst DE, Herman RA, Koehnke R et al (1990) Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 79:782–786CrossRefPubMed

24.

Myers BD, Ross J, Newton L, Luetscher J, Perlroth M (1984) Cyclosporine-associated chronic nephropathy. N Engl J Med 311:699–705CrossRefPubMed

25.

Burdmann EA, Andoh TF, Yu L, Bennett WM (2003) Cyclosporine nephrotoxicity. Semin Nephrol 23:465–476CrossRefPubMed

26.

Wolf G, Killen PD, Neilson EG (1990) Cyclosporin A stimulates transcription and procollagen secretion in tubulointerstitial fibroblasts and proximal tubular cells. J Am Soc Nephrol 1:918–922PubMed

27.

Roodnat JI, Christiaans MH, Nugteren-Huying WM et al (1989) Acute kidney insufficiency in the treatment of psoriasis using fumaric esters. Schweiz Med Wochenschr 119:826–830PubMed

28.

Raschka C, Koch HJ (1999) Longterm treatment of psoriasis using fumaric acid preparations can be associated with severe proximal tubular damage. Hum Exp Toxicol 18:738–739CrossRefPubMed

29.

Lee MR, Cooper AJ (2006) Biologic agents in psoriasis. Australas J Dermatol 47:217–229CrossRefPubMed

30.

Melgaço SS, Silva GB Jr, Dantas AM et al (2013) Evaluation of renal function in patients with psoriasis using immunobiologicals. An Bras Dermatol 88:667–669PubMedCentralCrossRefPubMed

31.

Little MA, Bhangal G, Smyth CL et al (2006) Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol 17:160–169CrossRefPubMed

32.

Yahya TM, Dhanyamraju S, Harrington TM, Prichard JW (2013) Spontaneous resolution of lupus nephritis following withdrawal of etanercept. Ann Clin Lab Sci 43:447–449PubMed

33.

Menè P, Franeta AJ, Conti G et al (2010) Extracapillary glomerulonephritis during etanercept treatment for juvenile psoriatic arthritis. Clin Exp Rheumatol 28:91–93PubMed

34.

Chin G, Luxton G, Harvey JM (2005) Infliximab and nephrotic syndrome. Nephrol Dial Transplant 20:2824–2826CrossRefPubMed

35.

Davidovici BB, Sattar N, Prinz J et al (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Investig Dermatol 130:1785–1796CrossRefPubMed

36.

Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM (2013) Risk of moderate to advanced kidney disease in patients with psoriasis: population-based cohort study. BMJ 347:f5961PubMedCentralCrossRefPubMed

37.

Chi CC, Wang J, Chen YF, Wang SH, Chen FL, Tung TH (2015) Risk of incident chronic kidney disease and end-stage renal disease in patients with psoriasis: a nationwide population-based cohort study. J Dermatol Sci 78:232–238CrossRefPubMed

38.

Gisondi P, Rossini M, Di Cesare A et al (2012) Vitamin D status in patients with chronic plaque psoriasis. Br J Dermatol 166:505–510CrossRefPubMed

Tags: Cardiovascular Diabetes Kidney Metabolic Syndrome